Qiang Cheng, Yin Lu, Bin Jiang, Qing Ai, Fan Gao, Xupeng Zhao, Jinlu Tang, Yi Feng, Wenfeng Gao, Hongzhao Li
{"title":"机器人体内原位新膀胱的肿瘤和功能结局及并发症:一项单中心回顾性研究。","authors":"Qiang Cheng, Yin Lu, Bin Jiang, Qing Ai, Fan Gao, Xupeng Zhao, Jinlu Tang, Yi Feng, Wenfeng Gao, Hongzhao Li","doi":"10.14440/bladder.2024.0025","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Robotic intracorporeal Studer orthotopic neobladder (RISON) is a complex procedure for bladder reconstruction.</p><p><strong>Objective: </strong>This study aimed to retrospectively examine the oncological/functional outcomes, and complications of RISON at a single center.</p><p><strong>Methods: </strong>Baseline data and perioperative results of patients who received RISON between March 2018 and December 2022 were analyzed. Sixty-two cases (60 males, 2 females), with a mean age of 56.79 ± 9.12 years, were included in the study. Follow-up data regarding RISON's therapeutic effects, including tumor outcomes, neobladder capacity, continence, and complications, were collected.</p><p><strong>Results: </strong>All patients underwent the procedure without conversion to open surgery or changes in urinary diversion. The mean operative time lasted 379.2 ± 88.8 min, with a median blood loss of 200 mL (range: 100-300 mL). Indwelling time of the Ryles tube was 3.78 ± 2.23 days, and post-operative hospital stay was 10 days (range: 8-12 days). Pathological examination showed 87.1% (54/62) of cases had T2N0M0 tumors. A mean of 17.42 ± 8.03 lymph nodes were dissected, with three cases developing lymph node metastasis. Short-term complications (within 30 days) occurred in 51.9% of patients, while long-term complications (after 30 days) were found in 51.9% of patients. The mean neobladder volume measured 344.31 ± 147.00 mL. Daytime continence was achieved in 88.2% of patients, and night-time continence was attained in 39.2%. The average night-time urinary frequency was 2.78 ± 1.55 times, with 1.9 urine pads used on average. Follow-up duration ranged from 27 to 73 months, with a median time of 52.5 months. Five patients died of tumor metastasis, spreading to bone, liver, lung, brain, or lymph nodes. The 36- and 60-month cumulative recurrence-free survival rates were 96.3% and 87.4%, respectively. The 36- and 60-month cumulative overall survival rates were 96.3% and 90.4%, respectively.</p><p><strong>Conclusion: </strong>Clinically, RISON is a safe and feasible procedure with excellent oncological and functional outcomes, showing promise for widespread application.</p>","PeriodicalId":72421,"journal":{"name":"Bladder (San Francisco, Calif.)","volume":"12 1","pages":"e21200029"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12308130/pdf/","citationCount":"0","resultStr":"{\"title\":\"Oncological and functional outcomes and complications of robotic intracorporeal Studer orthotopic neobladder: A single-center retrospective study.\",\"authors\":\"Qiang Cheng, Yin Lu, Bin Jiang, Qing Ai, Fan Gao, Xupeng Zhao, Jinlu Tang, Yi Feng, Wenfeng Gao, Hongzhao Li\",\"doi\":\"10.14440/bladder.2024.0025\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Robotic intracorporeal Studer orthotopic neobladder (RISON) is a complex procedure for bladder reconstruction.</p><p><strong>Objective: </strong>This study aimed to retrospectively examine the oncological/functional outcomes, and complications of RISON at a single center.</p><p><strong>Methods: </strong>Baseline data and perioperative results of patients who received RISON between March 2018 and December 2022 were analyzed. Sixty-two cases (60 males, 2 females), with a mean age of 56.79 ± 9.12 years, were included in the study. Follow-up data regarding RISON's therapeutic effects, including tumor outcomes, neobladder capacity, continence, and complications, were collected.</p><p><strong>Results: </strong>All patients underwent the procedure without conversion to open surgery or changes in urinary diversion. The mean operative time lasted 379.2 ± 88.8 min, with a median blood loss of 200 mL (range: 100-300 mL). Indwelling time of the Ryles tube was 3.78 ± 2.23 days, and post-operative hospital stay was 10 days (range: 8-12 days). Pathological examination showed 87.1% (54/62) of cases had T2N0M0 tumors. A mean of 17.42 ± 8.03 lymph nodes were dissected, with three cases developing lymph node metastasis. Short-term complications (within 30 days) occurred in 51.9% of patients, while long-term complications (after 30 days) were found in 51.9% of patients. The mean neobladder volume measured 344.31 ± 147.00 mL. Daytime continence was achieved in 88.2% of patients, and night-time continence was attained in 39.2%. The average night-time urinary frequency was 2.78 ± 1.55 times, with 1.9 urine pads used on average. Follow-up duration ranged from 27 to 73 months, with a median time of 52.5 months. Five patients died of tumor metastasis, spreading to bone, liver, lung, brain, or lymph nodes. The 36- and 60-month cumulative recurrence-free survival rates were 96.3% and 87.4%, respectively. The 36- and 60-month cumulative overall survival rates were 96.3% and 90.4%, respectively.</p><p><strong>Conclusion: </strong>Clinically, RISON is a safe and feasible procedure with excellent oncological and functional outcomes, showing promise for widespread application.</p>\",\"PeriodicalId\":72421,\"journal\":{\"name\":\"Bladder (San Francisco, Calif.)\",\"volume\":\"12 1\",\"pages\":\"e21200029\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12308130/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bladder (San Francisco, Calif.)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14440/bladder.2024.0025\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bladder (San Francisco, Calif.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14440/bladder.2024.0025","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
Oncological and functional outcomes and complications of robotic intracorporeal Studer orthotopic neobladder: A single-center retrospective study.
Background: Robotic intracorporeal Studer orthotopic neobladder (RISON) is a complex procedure for bladder reconstruction.
Objective: This study aimed to retrospectively examine the oncological/functional outcomes, and complications of RISON at a single center.
Methods: Baseline data and perioperative results of patients who received RISON between March 2018 and December 2022 were analyzed. Sixty-two cases (60 males, 2 females), with a mean age of 56.79 ± 9.12 years, were included in the study. Follow-up data regarding RISON's therapeutic effects, including tumor outcomes, neobladder capacity, continence, and complications, were collected.
Results: All patients underwent the procedure without conversion to open surgery or changes in urinary diversion. The mean operative time lasted 379.2 ± 88.8 min, with a median blood loss of 200 mL (range: 100-300 mL). Indwelling time of the Ryles tube was 3.78 ± 2.23 days, and post-operative hospital stay was 10 days (range: 8-12 days). Pathological examination showed 87.1% (54/62) of cases had T2N0M0 tumors. A mean of 17.42 ± 8.03 lymph nodes were dissected, with three cases developing lymph node metastasis. Short-term complications (within 30 days) occurred in 51.9% of patients, while long-term complications (after 30 days) were found in 51.9% of patients. The mean neobladder volume measured 344.31 ± 147.00 mL. Daytime continence was achieved in 88.2% of patients, and night-time continence was attained in 39.2%. The average night-time urinary frequency was 2.78 ± 1.55 times, with 1.9 urine pads used on average. Follow-up duration ranged from 27 to 73 months, with a median time of 52.5 months. Five patients died of tumor metastasis, spreading to bone, liver, lung, brain, or lymph nodes. The 36- and 60-month cumulative recurrence-free survival rates were 96.3% and 87.4%, respectively. The 36- and 60-month cumulative overall survival rates were 96.3% and 90.4%, respectively.
Conclusion: Clinically, RISON is a safe and feasible procedure with excellent oncological and functional outcomes, showing promise for widespread application.